Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up – Here’s Why

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $13.07, but opened at $13.6050. Bayer Aktiengesellschaft shares last traded at $13.4951, with a volume of 633,632 shares.

Analyst Ratings Changes

BAYRY has been the subject of several analyst reports. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. Finally, UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

The firm has a market capitalization of $53.90 billion, a price-to-earnings ratio of -21.43, a PEG ratio of 4.27 and a beta of 0.59. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The stock’s 50-day moving average is $10.99 and its 200-day moving average is $11.53.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.